Correlation Between Opthea and Novo Nordisk

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Opthea and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Opthea and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Opthea and Novo Nordisk AS, you can compare the effects of market volatilities on Opthea and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Opthea with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Opthea and Novo Nordisk.

Diversification Opportunities for Opthea and Novo Nordisk

0.61
  Correlation Coefficient

Poor diversification

The 3 months correlation between Opthea and Novo is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Opthea and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Opthea is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Opthea are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Opthea i.e., Opthea and Novo Nordisk go up and down completely randomly.

Pair Corralation between Opthea and Novo Nordisk

Considering the 90-day investment horizon Opthea is expected to generate 1.35 times more return on investment than Novo Nordisk. However, Opthea is 1.35 times more volatile than Novo Nordisk AS. It trades about -0.01 of its potential returns per unit of risk. Novo Nordisk AS is currently generating about -0.14 per unit of risk. If you would invest  397.00  in Opthea on September 27, 2024 and sell it today you would lose (34.00) from holding Opthea or give up 8.56% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Opthea  vs.  Novo Nordisk AS

 Performance 
       Timeline  
Opthea 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Opthea has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Opthea is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.
Novo Nordisk AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Opthea and Novo Nordisk Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Opthea and Novo Nordisk

The main advantage of trading using opposite Opthea and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Opthea position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.
The idea behind Opthea and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal